Displaying 13 - 24 items out of 32 results
Landing page
… non-small cell lung cancer (NSCLC). Her pioneering work on DNA damage response (DDR) pathways and immune activation … Multiple Myeloma program, a Lymphoma Program, a functional tumor registry, an Integrated Breast & Cervical Cancer … work on non-invasive molecular subtyping of NSCLC based on circulating tumor DNA established the foundation for liquid …
Press release
… a powerful tool that can determine the patient’s molecular tumor profile in order to determine the best therapeutic … applied as an alternative to tissue testing in cases where tumor testing is not possible or tissue is not adequate,” … rebiopsies. In this context, the isolation of tumor-derived DNA, RNA and cells from the peripheral circulation (a …
Landing page
… of lung cancers harboring mutations in genes involved in DNA damage repair (DDR) derive improved clinical … of the interaction of metabolite-miRNA in driving tumor initiation. Read Spotlight Grant Recipient Hua Zhang, …
Landing page
… Multiple Myeloma program, a Lymphoma Program, a functional tumor registry, an Integrated Breast & Cervical Cancer … non-small cell lung cancer (NSCLC). Her pioneering work on DNA damage response (DDR) pathways and immune activation … work on non-invasive molecular subtyping of NSCLC based on circulating tumor DNA established the foundation for liquid …
Landing page
… liquid biopsies, specifically in extracellular vesicles and circulating free tumor DNA. Dr. Rolfo has authored more than 250 scientific …
Landing page
… Multiple Myeloma program, a Lymphoma Program, a functional tumor registry, an Integrated Breast & Cervical Cancer … non-small cell lung cancer (NSCLC). Her pioneering work on DNA damage response (DDR) pathways and immune activation … work on non-invasive molecular subtyping of NSCLC based on circulating tumor DNA established the foundation for liquid …
Press release
… reported data from the KEYNOTE 021 trial that showed antitumor activity for pembrolizumab plus platinum-based … and pemetrexed or carboplatin and pemetrexed alone. Tumor mutational burden was determined by whole exome sequencing of tumor and matched normal DNA. Langer and the KEYNOTE 021 researchers were able to …
Landing page
… Multiple Myeloma program, a Lymphoma Program, a functional tumor registry, an Integrated Breast & Cervical Cancer … evaluating nivolumab for patients with thymic epithelial tumor and currently engaging multimodality therapy for … non-small cell lung cancer (NSCLC). Her pioneering work on DNA damage response (DDR) pathways and immune activation …
Press release
… specific cancer’s growth and progression. Patients whose tumors harbor certain, specific molecular alterations may be … EGFR T790M in relapse may be done by biopsy or cell-free circulating DNA. However cell-free DNA is not appropriate for initial …
Landing page
… work on non-invasive molecular subtyping of NSCLC based on circulating tumor DNA established the foundation for liquid biopsy as a …
Press release
… predictive biomarkers, which may enable better targeting of tumor characteristics. Its aims to accelerate development of … and novel diagnostic approaches – like the detection of circulating tumor DNA in blood samples – to identify patients with a poor …
Press release
… safety. Minimal residual disease (MRD) was assessed using circulating tumor DNA (Guardant Reveal). Mariano Provencio, MD, PhD, Hospital …